4-(2-trifluoromethylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester | 881391-42-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-trifluoromethylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl-4-{[2-(trifluoromethyl)phenyl]carbonyl}piperidine-1-carboxylate；tert-butyl 4-[2-(trifluoromethyl)benzoyl]piperidine-1-carboxylate
• CAS: 881391-42-0
• 化学式: C₁₈H₂₂F₃NO₃
• 分子量: 357.373
• InChiKey: FNVMXNDIWKREPR-UHFFFAOYSA-N

物化性质

• 沸点：
  416.9±45.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-trifluoromethylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以55%的产率得到piperidin-4-yl-(2-trifluoromethylphenyl)methanone
  参考文献：
  名称：

  [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE
  [FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE STEAROYLE-COA DESATURASE

  摘要：

  本发明揭示了治疗哺乳动物，尤其是人类患有SCD介导的疾病或症状的方法，其中所述方法包括向需要的哺乳动物施用以下化合物（I）的方法：化合物（I）其中x、y、G、J、L、M、V、W、R2、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此处被定义。还揭示了包含化合物（I）的药物组合物。

  公开号：

  WO2006034338A1
• 作为产物：
  描述：

  (7a)-4-[hydroxy-(2-trifluoromethyl-phenyl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成 4-(2-trifluoromethylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats

  摘要：

  Starting from a known piperazine-based SCD-1 inhibitor, we obtained more potent benzoylpiperidine analogs. Optimization of the structure of the benzoylpiperidine-based SCD-1 inhibitors resulted in the identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-yl-ethyl)amide (24) which showed strong inhibitory activity against both human and murine SCD-1. In addition, this compound exhibited good oral bioavailability and demonstrated plasma triglyceride lowering effects in Zucker fatty rats in a dose-dependent manner after a 7-day oral administration (qd). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.101

文献信息

• HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Isabel Elise

  公开号：US20110301143A1

  公开（公告）日：2011-12-08

  Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R 1 — substituted heteroaryl, R 1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR 5 R 6 , C═CR 5 or CR 13 —CR 5 R 6 , Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

  结构式（I）的杂环化合物，或其药学上可接受的盐，其中W是R1-取代的杂芳基，R1是取代有酯基或羧基的杂芳基环，X-T是N—CR5R6，C═CR5或CR13—CR5R6，Y是键或—C(O)—，a和b代表选自1到4的整数，Ar是可选择取代的苯基或萘基，是硬脂酰辅酶A 9-脱饱和酶（SCD）的抑制剂。这些杂环化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗、癌症、肝脂肪变性和非酒精性脂肪肝。
• Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase
  申请人：Kamboj Rajender

  公开号：US20070299081A1

  公开（公告）日：2007-12-27

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 6a , R 7 , R 7a , R 8 , and R 8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了治疗哺乳动物，特别是人类SCD介导的疾病或病状的方法，其中方法包括向需要该方法的哺乳动物施用式(I)的化合物：式(I)中x、y、G、J、L、M、V、W、R2、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a如本文所定义。还揭示了包含式(I)的化合物的药物组合物。
• Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US07951805B2

  公开（公告）日：2011-05-31

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8, and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了一种治疗哺乳动物（优选为人类）SCD介导的疾病或病状的方法，其中该方法包括向需要的哺乳动物中投与式（I）的化合物：式（I）其中x，y，G，J，L，M，V，W，R2，R3，R4，R5，R5a，R6，R6a，R7，R7a，R8和R8a在此被定义。本发明还揭示了包含式（I）化合物的制药组合物。
• A New Pathway for the Synthesis of Ketones from Aldehydes and Sulfonylhydrazones: Is Diazo the Key Intermediate?
  作者：Yue‐xing Wang、Li‐ping Chen、Feng‐de Cao、Bin Zhao、Zhen‐peng Li、Xiu‐fen Li、Long‐jiang Huang

  DOI：10.1002/chem.202301569

  日期：2023.9.26

  A scalable and efficient method suitable for the preparation of a wide variety of ketones via new intermediate V has been developed.

  开发了一种可扩展且高效的方法，适用于通过新的中间体V制备多种酮。
• [EN] HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
  申请人：MERCK CANADA INC

  公开号：WO2010094126A8

  公开（公告）日：2012-03-08